Exercise slashes risk of death in patients with colon cancer
Exercise slashes the risk of death in patients with colon cancer by more than a third, a trial has found.
Physical activity could also prevent the disease from coming back, as well as lifting mood, reducing fatigue and boosting strength, according to researchers.
Colon cancer develops in the part of the large intestine known as the colon, part of the large bowel, which also comprises the rectum and anus.
It can sometimes be referred to as bowel cancer or colorectal cancer.
Our study gives clear, encouraging evidence that physical activity can reduce the risk of cancer returning for some people with colon cancer
The CO21 Challenge trial, led by researchers in Northern Ireland and Canada, involved 889 people with colon cancer from six countries.
All patients had had surgery and chemotherapy for their cancer and were deemed well enough to exercise, but were not meeting recommended physical activity levels.
Around half were given a three-year tailored exercise programme, which included the likes of brisk walking, circuit classes, cycling, or swimming.
The plan included in-person coaching sessions for the first six months, as well as regular meetings with a physical activity consultant.
We now need to work with policymakers and healthcare providers to embed exercise into treatment plans where appropriate
The other group were offered materials that promoted exercise and nutrition.
The study found that after five years, the risk of dying, relapse or developing a new cancer was 28% lower in the group with a tailored exercise plan.
After eight years, patients in the physical activity group had a 37% lower risk of death.
Professor Vicky Coyle, UK lead researcher for the trial and clinical professor at Queen's University Belfast, said: 'During the trial, we supported people to reach their weekly exercise target in a way that worked for them.
'This could be a brisk walk for around 40 minutes every day, but some patients were also doing circuit classes, cycling, swimming, and many other activities.
We know that physical activity regulates several key biological processes that could explain these results, and further research will help us uncover why exercise is having such a positive impact
'Our study gives clear, encouraging evidence that physical activity can reduce the risk of cancer returning for some people with colon cancer.
'We now need to work with policymakers and healthcare providers to embed exercise into treatment plans where appropriate.'
Dr Joe Henson, associate professor in lifestyle medicine at the University of Leicester, said: 'Leading the exercise sessions in Leicester, I saw first-hand that this reduced fatigue, lifted people's mood, and boosted their physical strength.
'We know that physical activity regulates several key biological processes that could explain these results, and further research will help us uncover why exercise is having such a positive impact.'
The findings, published in the New England Journal of Medicine and presented at the American Society of Clinical Oncology (ASCO), could 'transform clinical practice', according to experts.
This trial has the potential to transform clinical practice, but only if health services have the necessary funding and staff to make it a reality for patients
Caroline Geraghty, senior specialist information nurse at Cancer Research UK, said: 'Being active has many benefits, and this study shows that exercise doesn't only improve well-being – it can also boost people's chances of surviving colon cancer.
'Everyone recovering from cancer should have access to tailored support to help them live longer, better lives.
'This trial has the potential to transform clinical practice, but only if health services have the necessary funding and staff to make it a reality for patients.
'It's important to remember that every cancer journey is different – starting new activities after treatment can feel overwhelming, and it may not be the right option for everyone. Take things at your own pace and speak to your doctor to discuss what is safe for you.'
Professor Peter Johnson, NHS national clinical director for cancer, said: 'These exciting findings add to the growing evidence of the benefits of physical activity for people affected by cancer, not just in helping them be fitter for treatment and boosting their immediate recovery, but reducing the risk of the disease coming back.
'This is why we've asked cancer alliances across the country to look at ways to encourage and support patients to do physical activity and ensure every healthcare professional they see can help them be in the best possible place – both physically and mentally – before, during and after treatment.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Examiner
2 days ago
- Irish Examiner
Women less likely to get care for potentially fatal heart condition, study finds
Women are less likely than men to be given treatment for a potentially fatal heart condition, according to a new analysis. Researchers found women are 11% less likely to be referred to a hospital specialist after a diagnosis of the heart valve disease aortic stenosis. Academics said the findings show 'inequities in management and care of this common and serious condition' after they also found differences in care among south Asian and black patients as well as those from poorer backgrounds. Aortic stenosis, a narrowing of the aortic valve or the area immediately around it, leads to obstruction of the blood flow from the heart, which leads to symptoms including dizziness, fatigue, chest pain and breathlessness. The condition is more common in elderly people. It is not possible to reverse but treatments can include a transcatheter aortic valve implantation (TAVI) or valve replacement surgery. If left untreated it can lead to serious complications, including heart failure, heart rhythm abnormalities, and death. The analysis suggests some people are less likely to receive this treatment. Experts from the University of Leicester examined GP data on 155,000 people diagnosed with aortic stenosis between 2000 and 2022 in England. Presenting their findings to the British Cardiovascular Society conference in Manchester, experts said as well as women being less likely to be referred for hospital care, they are 39% less likely to have a procedure to replace their aortic valve. Researchers also found people living in poorer neighbourhoods are 7% less likely to be referred for hospital care after a diagnosis compared to people from wealthier neighbourhoods. Meanwhile, black patients are 48% less likely to undergo a procedure to replace their aortic valve compared to white patients. South Asian patients are 27% less likely to undergo a procedure compared to their white counterparts, according to the study, which was funded by the National Institute for Health and Care Research (NIHR) and supported by NIHR Leicester Biomedical Research Centre. Dr Anvesha Singh, associate professor at the University of Leicester and consultant cardiologist, who was involved in the research, said: 'Previous studies have shown lower rates of valve replacement in women, and clinicians had assumed that women were less likely to be diagnosed with aortic stenosis. 'This analysis using large, real-world data clearly shows that this is not the case, giving us the clearest picture yet of what is happening in day-to-day clinical practice. 'Our study highlights potential inequities in management and care of this common and serious condition. More research is needed to understand the reasons for this and the true prevalence of aortic stenosis in different groups.' Dr Sonya Babu-Narayan, clinical director at the British Heart Foundation, which supported the research, and consultant cardiologist, said: 'This study of over 150,000 GP records has unveiled disparities in access to aortic valve treatment for women, south Asian and black people, and people living in more deprived communities. 'We don't yet have the full picture, but these findings are concerning and we need more research to understand what is driving the differences seen. 'This will be crucial to enable action to address any underlying causes stopping some people from having access to the heart valve treatment and care they need, when they need it.'
Irish Independent
3 days ago
- Irish Independent
Long term survival for lung cancer patients improved with new treatment combination, new Irish research reveals
The patients with lung cancer who received an immunotherapy drug, nivolumab, along with standard chemotherapy before surgery had improved long term survival compared to those who received chemotherapy alone, at five years after completing treatment. Results from the phase 3 clinical trial were published in the New England Journal of Medicine. Prof Patrick Forde of the Trinity St James's Cancer Institute (TSJCI), Trinity College Dublin School of Medicine, presented the findings at the American Society of Clinical Oncology Annual Meeting in Chicago, USA, at the weekend. Prof Forde led the CheckMate 816 trial which enrolled 358 patients globally who were diagnosed with the most common type of lung cancer, non-small cell lung cancer (NSCLC), at a stage where it could be removed by surgery. However, despite undergoing surgery, 50pc of patients with stage 2 or 3 lung cancer will eventually have relapse of their cancer. Immunotherapy drugs known as immune checkpoint inhibitors, in particular those that block a receptor called PD-1, have led to improved survival for patients with advanced cancers by unmasking the tumour to the patient's immune system. However, up until now, no study had shown long-term benefit to this treatment in helping to cure earlier stage lung cancer. Earlier in his career as an oncologist at Johns Hopkins in the United States Prof Forde led the first clinical trial of immunotherapy prior to surgery (neoadjuvant therapy) for lung cancer which was published in the New England Journal of Medicine in 2018. That study showed that among 20 patients who underwent surgery after two doses of immunotherapy, almost half had little or no remaining cancer at the time of their operation. In an earlier report of the CheckMate 816 trial, patients with lung cancer who received immunotherapy along with chemotherapy prior to surgery were more likely to have had their cancer eliminated completely by the time of surgery and also had lower rates of cancer relapse. Side effects were not increased with the addition of immunotherapy, and in general, surgeries went well. These findings led to the approval of the neoadjuvant nivolumab plus chemotherapy in several countries globally, including as a standard treatment for eligible patients in Ireland. In the latest update from the trial, patients who received immunotherapy plus chemotherapy before surgery were approximately 10pc more likely to be alive at five years than those who just received chemotherapy. Among the 24pc of patients treated with immunotherapy plus chemotherapy who had no cancer remaining at the time of surgery - known as a pathologic complete response - no patient had died from lung cancer by five years. Prof Forde is also co-leading an international clinical trial open in Ireland at TSJCI, Beaumont, Galway and Mater Hospitals that is aimed at further improving outcomes for patients undergoing surgery. Results from part of this study were also published this week in the prestigious Nature Medicine journal. In the NeoCOAST-2 trial, patients who received standard chemo-immunotherapy plus a new treatment called an antibody drug conjugate (ADC) before surgery were more likely to have no viable cancer remaining at the time of surgery, suggesting that this additional treatment could improve outcomes further. Prof Forde said: 'Immunotherapy has helped many patients with stage 4 lung cancer live longer with good quality of life. "Until recently we have not had new treatments available that can increase the chances of cure after lung cancer surgery. The use of immunotherapy with chemotherapy before lung cancer surgery has now been shown to reduce the risk of cancer coming back and improve long term survival. "Cancer clinical trials are key to improving outcomes for patients with cancer and offer the potential for early access to the latest cutting edge cancer treatments. I am delighted to be able to help expand clinical trial options for patients in Ireland.' In 2024, Prof Forde joined the Trinity St James's Cancer Institute (TSJCI) as the Patrick Prendergast Professor of Clinical Immuno-Oncology. This position was established by a philanthropic gift from Dr Stanley Quek, Trinity alumnus and former Pro-Chancellor of the University. In collaboration with colleagues across Ireland, Prof Forde's goal is to improve access for patients to cutting edge cancer clinical trials.
RTÉ News
3 days ago
- RTÉ News
Exercise may reduce risk of cancer returning, study shows
An international cancer study has found that exercise can have huge benefits for cancer patients and can even reduce the risk of the disease returning. The results were presented at the American Society of Clinical Oncology annual conference in Chicago at the weekend, and published in the New England Journal of Medicine. Among those attending the expert gathering was Professor Janice Walshe, medical oncologist at St Vincent's University Hospital in Dublin. She called the study an "incredibly strong finding", saying "it adds to the literatures that suggests that exercise is really important in keeping ourselves well." The study examined nearly 890 patients who had high risk colon cancers (stage 2 or stage 3) and was completed in 55 locations, including in countries such as the US, France and Australia. All patients had completed chemotherapy treatments and were put into one of two groups. One group was given structured, supervised exercise sessions with a personal trainer and the other was just given a booklet outlining the benefits of a healthy lifestyle. The first group did 45 to 60 minute walks three or four times a week and could do more if they chose. Twice a month they worked with a personal trainer and then later once a month for a total of three years. After eight years, the patients in the first group had a 37% lower risk of dying than those in the second group. Prof Walshe said it was important to note that all these patients had already received chemotherapy. "So, this intervention is not a substitute for drugs that we know already reduce the risk of people dying from different various cancers," Prof Walsh said. Speaking to RTÉ's Morning Ireland, Prof Walshe said she felt that some newspaper headlines about the study were "misleading." "I think what they're trying to say is that the magnitude of benefit we have seen with this intervention, of an exercise programme, is the type of reductions we've seen with many of our new drugs. "But this is not a drug substitute," Prof Walshe said. "This is on top of you receiving the best drugs in the market to reduce the risk of disease recurrence." Prof Walshe said there is a "huge amount of Irish research" at this year's American Society of Clinical Oncology conference. "The consultants who travel here are all networking with various research groups to bring these trials home to Ireland and obviously the best approaches in terms of managing our cancer in our Irish patients," she said. "We already have exercise programmes ongoing in various parts of the country that are free of charge, because we believe exercise is really important in terms of, one, reducing risk of disease recurrence and, two, increasing people's confidence," she added.
